LONDON – There are two repurposings for the price of one in the launch today of Iceni Pharmaceuticals Ltd., with the former DNA vaccines company transmuting into a cancer specialist and bringing cilengitide, an integrin inhibitor that previously failed in a phase III trial in glioma, back into the clinic as a treatment for multiple myeloma.